Patents by Inventor Bruce M. Spiegelman

Bruce M. Spiegelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for induced brown fat differentiation
    Patent number: 11766471
    Abstract: The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm16 and C/EBP? activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm16 and C/EBP? expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm16 and C/EBP? expression and/or activity.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 26, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Shingo Kajimura
  • METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2
    Publication number: 20220193193
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using Slit2.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 23, 2022
    Inventors: Bruce M. Spiegelman, Katrin J. Svensson
  • Chemical uncouplers of respiration and methods of use thereof
    Patent number: 11365177
    Abstract: Uncoupling of respiration is a well-recognized process that increases respiration and heat production in cells. Provided herein are chemical uncouplers of respiration that are compounds of Formula (I). Also provided are methods for preventing or treating metabolic disorders and modulating metabolic processes using compound of Formula (I).
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 21, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., University of Florida Research Foundation, Incorporated
    Inventors: Bruce M. Spiegelman, Jonathan Z. Long, Hua Lin, Theodore Kamenecka, Patrick Griffin
  • Compositions and methods for regulating pancreatic beta cell function using adipsin
    Patent number: 11331379
    Abstract: The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 17, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, James Lo
  • Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2
    Patent number: 11291706
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using Slit2.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 5, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Katrin J. Svensson
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5
    Publication number: 20220062389
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Application
    Filed: September 13, 2021
    Publication date: March 3, 2022
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • Methods for the treatment of neurological disorders and diseases using FNDC5
    Patent number: 11129879
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: September 28, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • Compositions and methods for brown fat induction and activity using FNDC5
    Patent number: 11098092
    Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: August 24, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pontus Bostrom
  • METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS
    Publication number: 20210106661
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using PM20D1 and N-lipidated amino acids.
    Type: Application
    Filed: October 28, 2016
    Publication date: April 15, 2021
    Inventors: Bruce M. Spiegelman, Jonathan Z. Long
  • METHODS FOR PREVENTING AND/OR TREATING BONE LOSS CONDITIONS BY MODULATING IRISIN
    Publication number: 20210063414
    Abstract: The present invention relates, in part, to methods of preventing and/or treating a subject afflicted with bone loss conditions comprising administering to the subject a therapeutically effective amount of an agent that decreases the amount and/or activity of irisin.
    Type: Application
    Filed: February 12, 2019
    Publication date: March 4, 2021
    Inventors: Bruce M. Spiegelman, Hyeonwoo Kim, Clifford Rosen, Lynda Bonewald
  • CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF
    Publication number: 20200317613
    Abstract: Uncoupling of respiration is a well-recognized process that increases respiration and heat production in cells. Provided herein are chemical uncouplers of respiration that are compounds of Formula (I). Also provided are methods for preventing or treating metabolic disorders and modulating metabolic processes using compound of Formula (I).
    Type: Application
    Filed: November 29, 2018
    Publication date: October 8, 2020
    Inventors: Bruce M. Spiegelman, Jonathan Z Long, Hua Lin, Theodore Kamenecka, Patrick Griffin
  • Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
    Patent number: 10717992
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 21, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • COMPOSITIONS AND METHODS FOR INDUCED BROWN FAT DIFFERENTIATION
    Publication number: 20200206317
    Abstract: The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm16 and C/EBP? activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm16 and C/EBP? expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm16 and C/EBP? expression and/or activity.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 2, 2020
    Inventors: Bruce M. Spiegelman, Shingo Kajimura
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASE USING FNDC5
    Publication number: 20200108125
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 9, 2020
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • COMPOSITIONS AND METHODS FOR REGULATING PANCREATIC BETA CELL FUNCTION USING ADIPSIN
    Publication number: 20200093900
    Abstract: The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.
    Type: Application
    Filed: May 9, 2019
    Publication date: March 26, 2020
    Inventors: Bruce M. Spiegelman, James Lo
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
    Patent number: 10429384
    Abstract: The invention provides methods and compositions for selectively promoting anti-metabolic disorder activity over classical PPAR gamma activation through modulation of PPAR gamma phosphorylation (e.g., Ser-273 phosphorylation of murine peroxisome proliferator activated receptor gamma (PPAR gamma) 2 or a corresponding serine residue in a murine PPAR gamma 2 homolog, including a human). Also provided are methods for preventing, treating, or predictiving responsiveness of therapies for metabolic disorders in a subject through selective inhibition of such PPAR gamma phosphorylation. Further provided are methods for identifying compounds that are capable of modulating such PPAR gamma phosphorylation.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: October 1, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Jang Hyun Choi, Shingo Kajimura, Alexander Banks
  • COMPOSITIONS AND METHODS FOR BROWN FAT INDUCTION AND ACTIVITY USING FNDC5
    Publication number: 20190218259
    Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
    Type: Application
    Filed: September 4, 2018
    Publication date: July 18, 2019
    Inventors: Bruce M. Spiegelman, Pontus Bostrom
  • Compositions and methods for regulating pancreatic beta cell function using adipsin
    Patent number: 10328131
    Abstract: The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: June 25, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, James Lo
  • Methods for the treatment of neurological disorders and diseases using FNDC5
    Patent number: 10286042
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 14, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • Compositions and methods for brown fat induction and activity using FNDC5
    Patent number: 10093705
    Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: October 9, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pontus Bostrom